No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression

被引:16
|
作者
Evers, Jelle [1 ]
Grotenhuis, Anne J. [1 ]
Aben, Katja K. H. [1 ,2 ]
Kiemeney, Lambertus A. L. M. [1 ,3 ]
Vrieling, Alina [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Hlth Evidence, Nijmegen, Netherlands
[2] Netherlands Comprehens Canc Org, Utrecht, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Urol, Nijmegen, Netherlands
来源
PLOS ONE | 2020年 / 15卷 / 03期
关键词
BODY-MASS; PREDICTING RECURRENCE; UROTHELIAL CARCINOMA; METFORMIN USE; RISK; OBESITY; IMPACT; SUSCEPTIBILITY; PROGNOSIS; OUTCOMES;
D O I
10.1371/journal.pone.0229384
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Non-muscle invasive bladder cancer patients are at high risk for tumour recurrence and progression, hence an intensive follow-up procedure is recommended which is costly. Identification of factors that are associated with the risk of recurrence and progression may enable personalized follow-up schedules. Obesity and diabetes mellitus may be associated with a worse prognosis, but the evidence is limited and inconsistent. Our objective was to determine the associations of BMI and diabetes mellitus with risks of recurrence and progression among non-muscle invasive bladder cancer patients. Methods A population-based cohort of patients diagnosed with non-muscle invasive bladder cancer between 1995 and 2010 was retrospectively identified from the Netherlands Cancer Registry and invited to participate in the Nijmegen Bladder Cancer Study (n = 1,433). Average weight during adult life, height, and diabetes mellitus diagnosis were self-reported by use of a questionnaire. Clinical follow-up data were retrieved from medical files. Associations were quantified using proportional hazard analyses. For all analyses, minimal adjustment sets were selected using a Directed Acyclic Graph. Results Fourteen percent of the patients indicated to be diagnosed with diabetes mellitus, and more than half was overweight (45%) or obese (9%). Compared to healthy weight, overweight and obesity were not associated with risk of recurrence (adjusted hazard ratio (HR) = 1.02; 95% confidence interval (CI): 0.86-1.22, and HR = 1.02; 95% CI: 0.76-1.38, respectively) and overall progression (HR = 1.04; 95% CI: 0.74-1.44, and HR = 1.20; 95% CI: 0.69-2.09, respectively). Also, no clear associations of diabetes mellitus with risk of recurrence (HR = 1.22; 95% CI: 0.98-1.54) and overall progression (HR = 1.16; 95% CI: 0.76-1.76) were found. Conclusion Average BMI during adult life and diabetes mellitus were not clearly associated with risk of recurrence or progression in non-muscle invasive bladder cancer. Prospective cohort studies with detailed information on BMI and diabetes mellitus before and after diagnosis are needed to confirm these findings.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] The Costs of Non-Muscle Invasive Bladder Cancer
    James, Andrew C.
    Gore, John L.
    UROLOGIC CLINICS OF NORTH AMERICA, 2013, 40 (02) : 261 - +
  • [32] Aftercare of non-muscle invasive bladder cancer
    Schulz, G. B.
    Schlenker, B.
    Stief, C. G.
    UROLOGE, 2019, 58 (08): : 943 - 952
  • [33] Hyperthermia for non-muscle invasive bladder cancer
    Soria, Francesco
    Allasia, Marco
    Oderda, Marco
    Gontero, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (03) : 313 - 321
  • [34] Non-Muscle Invasive Bladder Cancer Preface
    Chang, Sam S.
    UROLOGIC CLINICS OF NORTH AMERICA, 2013, 40 (02) : XIII - XIII
  • [35] NON-MUSCLE INVASIVE BLADDER CANCER IN 2012
    Esuvaranathan, Kesavan
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 : 123 - 123
  • [36] Immunotherapy for non-muscle invasive bladder cancer
    Cathomas, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 17 - 17
  • [37] IMMUNOTHERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
    Black, Peter
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 37 - 37
  • [38] Diagnosis of Non-Muscle Invasive Bladder Cancer
    Palou, Joan
    Boehle, Andreas
    Witjes, J. Alfred
    Colombel, Marc
    Brausi, Maurizio
    Lamm, Donald
    Persad, Raj
    Buckley, Roger
    Akaza, Hideyuki
    Soloway, Mark
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (10) : 627 - 636
  • [39] Methylation and clinicopathological markers for predicting progression of non-muscle invasive bladder cancer
    Smal, M. P.
    Rolevich, A. I.
    Nabebina, T. I.
    Krasny, S. A.
    Goncharova, R. I.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 523 - 524
  • [40] PROGRESSION TO MUSCLE INVASIVE DISEASE OF G1-2/LOW GRADE NON-MUSCLE INVASIVE BLADDER CANCER: NEVER AT THE FIRST RECURRENCE
    Palou, Juan
    Rodriguez Faba, Oscar
    Maria Gaya, Josep
    Skrobot, Sergio
    Algaba, Ferran
    Novoa, R.
    Esquena, Salvador
    Villavicencio, Humberto
    JOURNAL OF UROLOGY, 2014, 191 (04): : E698 - E699